 Proto-Oncogene Proteins c-abl
"Proto-Oncogene Proteins c-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation.
| Descriptor ID |
D016315
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.500 D12.776.624.664.700.167
|
| Concept/Terms |
Proto-Oncogene Proteins c-abl- Proto-Oncogene Proteins c-abl
- Proto Oncogene Proteins c abl
- c-abl, Proto-Oncogene Proteins
- Proto-Oncogene Proteins abl
- Proteins abl, Proto-Oncogene
- Proto Oncogene Proteins abl
- abl, Proto-Oncogene Proteins
- c-abl Proteins
- c abl Proteins
- abl Proto-Oncogene Products
- Products, abl Proto-Oncogene
- Proto-Oncogene Products, abl
- abl Proto Oncogene Products
- abl Proto-Oncogene Proteins
- Proto-Oncogene Proteins, abl
- abl Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-abl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-abl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles.
-
Schmoker AM, Weinert JL, Markwood JM, Albretsen KS, Lunde ML, Weir ME, Ebert AM, Hinkle KL, Ballif BA. FYN and ABL Regulate the Interaction Networks of the DCBLD Receptor Family. Mol Cell Proteomics. 2020 10; 19(10):1586-1601.
-
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015 May; 21(5):440-8.
-
Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol. 2015 May; 35(5):1071-9.
-
Letsiou E, Rizzo AN, Sammani S, Naureckas P, Jacobson JR, Garcia JG, Dudek SM. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 Feb 01; 308(3):L259-69.
-
Wie SM, Adwan TS, DeGregori J, Anderson SM, Reyland ME. Inhibiting tyrosine phosphorylation of protein kinase Cd (PKCd) protects the salivary gland from radiation damage. J Biol Chem. 2014 Apr 11; 289(15):10900-10908.
-
Yaba A, Kayisli UA, Johnson J, Demir R, Demir N. The Abelson tyrosine kinase (c-Abl) expression on the mouse uterus and placenta during gestational period. J Mol Histol. 2011 Apr; 42(2):91-6.
-
Wu W, Berg LJ. c-Abl, an additional tyrosine kinase required for T cell development and function. Cell Cycle. 2008 Dec 15; 7(24):3791.
-
Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins. 2006 Nov 01; 65(2):331-46.
-
Tokonzaba E, Capelluto DG, Kutateladze TG, Overduin M. Phosphoinositide, phosphopeptide and pyridone interactions of the Abl SH2 domain. Chem Biol Drug Des. 2006 Mar; 67(3):230-7.
-
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6987-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|